Related Experiment Video
Updated: Aug 15, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
NSAIDs and the gastrointestinal mucosa
1Boston University School of Medicine, USA.
Abstract:
In the United States, these double-edged drugs cause as many as 20,000 deaths a year. To blunt their harmful effects, two promising strategies are being pursued: concurrent administration of prostaglandin analogues to support gastric homeostasis, and the development, or identification among existing NSAIDs, of an agent that targets inflammatory prostaglandins while sparing the homeostatic ones.
More Related Videos
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology

